Business Context and Reporting Period
This Form 8-K is filed by Amedica Corporation (not Sintx Technologies, Inc.) on February 19, 2014. The report details the closing of the Company's initial public offering (IPO) and the concurrent amendment and restatement of its Certificate of Incorporation and Bylaws.
Key Financial Metrics
- Capital Raised: The Company sold 3,500,000 shares of common stock at $5.75 per share.
- Gross Proceeds: Total gross proceeds were $20,125,000, subject to underwriting discounts and commissions.
- Over-Allotment Option: Underwriters were granted a 30-day option to purchase an additional 525,000 shares.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the transition to a public company status via the IPO closing. Additionally, the Company implemented significant corporate governance changes:
- Capital Structure: Authorized capital stock set at 250,000,000 shares of common stock and 130,000,000 shares of undesignated preferred stock.
- Preferred Stock: All references to previously existing series of preferred stock were eliminated.
- Board Authority: The Board was granted authority to amend bylaws without stockholder approval and to set the number of directors.
- Stockholder Voting: A supermajority of 80% of voting power is now required to amend bylaws or remove the entire Board. Stockholders can no longer act by written consent; all actions must occur at duly called meetings.
- Board Structure: A classified board of directors with three classes was established.
Outlook, Risks, and Contingencies
The filing does not contain specific management guidance, outlook, or risk factors beyond the standard incorporation of the prospectus filed on February 12, 2014. The Restated Bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain legal actions.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and commissions.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 525,000 shares.
- Review the full text of the Restated Certificate of Incorporation (Exhibit 3.1) and Restated Bylaws (Exhibit 3.2) for specific anti-takeover provisions.
- Check the prospectus filed on February 12, 2014, for detailed financial statements and risk factors not included in this 8-K.